Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ISRG vs RBOT.WS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ISRG Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

ISRG Overall Winner 6-Pillar Tally: ISRG 6 – 0 RBOT.WS Matrix Metrics: ISRG 9 – 1 RBOT.WS

As of Nov 20, 2026, Intuitive Surgical Inc. (ISRG) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ISRG carries a Unified Composite Score of 43.8/100 (HOLD) at $399.05 (32.0x Forward P/E, 31.7% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ISRG 43.8/100 HOLD), ISRG captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (31.7% vs. N/A operating margin) and revenue trajectory (+21.7% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ISRG vs RBOT.WS
ISRG NASDAQ Head-to-Head Winner
Intuitive Surgical Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$399.05
-2.01% 1D
Market Cap $141.2B
TTM Revenue $11.6B
Forward P/E 32.0x
Beta / 30D Vol 0.81β · 44% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 32.0 Fund 47.0 Flow 58.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.1 · SMA20: $442.13 · SMA50: $423.51
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (ISRG 6 – 0 RBOT.WS)

Columns: Metric · ISRG · RBOT.WS
1. Valuation Multiples ISRG
Forward P/E 32.0x N/M
Trailing P/E 49.2x N/M
PEG Ratio 1.90x N/M
EV / Revenue 12.2x N/M
2. Growth & Scale ISRG
Revenue Growth (YoY) +21.7% N/A
Earnings Growth (YoY) -23.6% N/A
TTM Revenue (USD) $11.6B N/A
Market Cap $141.2B N/A
3. Profitability & Quality ISRG
Gross Margin 66.6% N/A
Operating Margin 31.7% N/A
Net Profit Margin 25.5% N/A
Return on Equity (ROE) 17.9% N/A
4. Balance Sheet & Cash Flow ISRG
Cash Generation (TTM) $3.60B N/A
Cash Flow Margin 31.1% N/A
Net Cash / Leverage $46.12 Book/Sh · 17.9% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ISRG
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 132.6% (69th %ile) N/A (N/A)
Put/Call OI Skew 0.84x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ISRG
OpEx & R&D Intensity 34.9% of Rev ($4.04B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ISRG (9) vs RBOT.WS (1)
Institutional Metric ISRG RBOT.WS Criterion Row Edge
Market Capitalization
Scale
$141.2B N/A Larger Scale ISRG
Trailing P/E Ratio
Valuation
49.2x N/M Lower Multiple ISRG
Forward P/E Ratio
Valuation
32.0x N/M Lower Multiple ISRG
Revenue Growth (YoY)
Growth
+21.7% N/A Higher Growth ISRG
Operating Margin (TTM)
Profitability
31.7% N/A Higher Margin ISRG
Net Profit Margin
Profitability
25.5% N/A Higher Margin ISRG
Return on Equity (ROE)
Capital Efficiency
17.9% N/A Higher ROE ISRG
52-Week Range Position
Momentum
26% ($329–$604) 0% ($0–$0) Stronger Trend ISRG
Beta / 30D Volatility
Risk Regime
0.81β · 44% Vol N/A Lower Realized Risk ISRG
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 50.1 / 100 (HOLD) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
$11.6B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.90x PEG · 12.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.60B ($46.12 Book/Sh · 17.9% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ISRG +68.5 pp
ISRG: +1.3% · RBOT.WS: -67.2%
3M Horizon ISRG +68.5 pp
ISRG: +1.3% · RBOT.WS: -67.2%
6M Horizon ISRG +68.5 pp
ISRG: +1.3% · RBOT.WS: -67.2%
1Y Horizon ISRG +68.5 pp
ISRG: +1.3% · RBOT.WS: -67.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ISRG vs RBOT.WS. Trailing 12-month operating profitability (ISRG 31.7% vs RBOT.WS N/A) and valuation multiples (ISRG 32.0x vs RBOT.WS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ISRG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11.6B
Gross Margin66.6%
Op. Margin31.7%
ROE / Fwd P/E17.9% · 32.0x
RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ISRG SURGE
12d in phase · OBV DISTRIBUTION
Current IV 132.6%
IV Percentile 69th %ile
Put/Call OI Skew 0.84x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ISRG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $437.75 · IV 35.3%

ISRG Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($43,775)

Compare $43,775 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 35.3% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $440 / $470 Bull Call Spread

Buy 1x $440C · Sell 1x $470C · 31d

Net Entry $1,128 Debit
T+5d @ +5% Move +$562 (+50%)
Max Risk / Buffer $1,128 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $410 / $390 Bull Put Spread

Sell 1x $410P · Buy 1x $390P · 31d

Net Entry $385 Credit
Max Credit / Yield +$385 (+23.8% RoM)
Max Risk / Buffer -7.2% Cushion ($1,615 Mgn)
5d Edge & Liquidity 76% PoP · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Dec 18 $410P / $440-$470C Seagull

Sell 1x $410P · Buy 1x $440/$470C · 31d

Net Entry $468 Debit
T+5d @ +5% Move +$1,021 (+14.4% RoM)
Max Risk / Buffer -6.3% Put Cushion ($7,108 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ISRG Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $141.2B market capitalization and 31.7% operating margin.
OpEx & R&D Reinvestment 34.9% of Rev ($4.04B)
90D Engineering Disclosures 0 Published · Robot Manipulation
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ISRG vs RBOT.WS Key Questions & Quantitative Answers

As of Nov 20, 2026, Intuitive Surgical Inc. (ISRG) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ISRG carries a Unified Composite Score of 43.8/100 (HOLD) at $399.05 (32.0x Forward P/E, 31.7% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ISRG 43.8/100 HOLD), ISRG captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (31.7% vs. N/A operating margin) and revenue trajectory (+21.7% vs. N/A YoY).

ISRG leads the Growth & Scale pillar: ISRG posts +21.7% YoY revenue growth and -23.6% YoY earnings growth on $11.6B TTM revenue (66.6% gross margin, 31.7% operating margin), compared with RBOT.WS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ISRG generates $11.6B in USD-normalized revenue versus N/A for RBOT.WS. In operating R&D and SG&A reinvestment, ISRG deploys 34.9% of Rev ($4.04B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RBOT.WS.

ISRG screens cheaper on headline valuation multiples. ISRG trades at 32.0x Forward P/E, 49.2x Trailing P/E, 1.90x PEG, and 12.2x EV/Revenue (31.1% FCF margin), whereas RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ISRG (17.9% ROE) versus RBOT.WS (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ISRG carries 132.6% implied volatility (69th %ile, Elevated (60th–80th %ile)), a 0.84x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.81β · 44% Vol realized risk). By comparison, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.